



New York State Medicaid Drug Utilization Review (DUR) Board Meeting
The DUR Board will meet on November 18, 2021 from 9:00 a.m. to 1:00 p.m.

This meeting will be available for public viewing by way of live audio-video webcast and from Meeting Room 2, Concourse Level, Empire State Plaza, Albany NY

The link to the webcast is available from the Department of Health Events/Webcasts webpage: https://www.health.ny.gov/events/webcasts/

Agenda Items

A. Drug Utilization Review

The DUR Board will review the following topics and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate drug utilization:

- 1. Central Nervous System Stimulants - concurrent use with other controlled substances

B. Pharmacy Program Updates

The DUR Board will be provided updates on the following topics:

- 1. Statewide Formulary for Opioid Dependence Agents and Opioid Antagonists
2. Supplemental Rebate Initiatives
3. Respiratory Syncytial Virus (RSV) Season and palivizumab
4. Direct Acting Antivirals for Hepatitis C Virus

Agenda Timeline (subject to change based on meeting proceedings)

Table with 2 columns: Time and Agenda Item. Rows include: 9:00 - 9:15 Welcome and Opening Comments; 9:15 - 10:15 Public Comment Period; 10:15 - 11:15 Drug Utilization Review; 11:15 - 12:45 Pharmacy Program Updates; 12:45 - 1:00 Final Comments and Adjournment.

Interested parties must submit a request to provide public comment during the DUR Board meeting and must complete the registration process by November 10, 2021. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov (please reference DUR Board Meeting Speaker Request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes) and the total comment period will not exceed sixty (60) minutes. The Department of Health (DOH) reserves the right to limit the number of interested parties providing public comment in order to meet agenda timelines and accomplish meeting objectives.

Clinical information must be submitted in an electronic format by November 4, 2021 or the DUR Board may not have ample time to review the information. All written statements must be received in an electronic format by November 10, 2021. Written statements should summarize key points and may not exceed two (2) pages in length. Any clinical studies cited should be referenced, with the primary source of funding included.

All information must be sent to the DOH. Interested parties should not contact or send any information directly to DUR Board members.